Altacor
Altacor is a UK-based specialist ophthalmology company that develops and sells the Clinitas brand of sodium hyaluronate dry eye treatments and carbomer lubricating gel to individual consumers and eye care professionals, primarily through UK direct-to-consumer e-commerce.
- Company typePrivate
- Founded2005
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
Altacor firmographics
Firmographics- Name
- Altacor
- Legal name
- Altacor
- Website
- http://www.altacor-pharma.com/
- Company type
- Private
- Founded year
- 2005
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Altacor is a UK-based specialist ophthalmology company that develops and sells the Clinitas brand of sodium hyaluronate dry eye treatments and carbomer lubricating gel to individual consumers and eye care professionals, primarily through UK direct-to-consumer e-commerce.
- Ownership category
- akta.pro rank
Altacor industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Ophthalmic Goods Manufacturing (339115), Optical Goods Retailers (45613), Ophthalmic Goods Merchant Wholesalers (423460)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)
Keywords
Where Altacor is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Altacor business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Consumer Product Sales: Altacor generates revenue through direct-to-consumer sales of its Clinitas branded ophthalmic products (eye drops and gel) via e-commerce. Products are sold as one-time purchases with volume discounts available for multi-pack orders.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Clinitas 0.2% Ease eye drops - From £8.99 |
| Unit Pricing | Pay-as-you-go | Clinitas 0.4% Soothe eye drops - From £9.99 |
| Unit Pricing | Pay-as-you-go | Clinitas Gel Hydrate - From £5.99 |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Altacor product offering
Product offeringCore offering
Altacor develops, manufactures, and sells the Clinitas brand of ophthalmic products for the treatment of dry eye symptoms. The portfolio includes two sodium hyaluronate eye drop concentrations (Clinitas 0.2% Ease and Clinitas 0.4% Soothe) and a carbomer 980-based lubricating gel (Clinitas Gel Hydrate), formulated with high-molecular weight sodium hyaluronate to provide long-lasting ocular surface hydration. Products are sold primarily via the company's UK direct-to-consumer e-commerce store (clinitas.co.uk), with institutional use by the NHS.
Product overview
Altacor is a UK-based specialist ophthalmology company acquired by Fidia Farmaceutici in April 2026. The company offers the Clinitas brand of dry eye treatment products, which includes sodium hyaluronate-based eye drops in two concentrations (0.2% Ease and 0.4% Soothe) and a carbomer-based lubricating gel (Clinitas Gel Hydrate). These products provide targeted relief for dry eye symptoms through scientifically formulated ophthalmic solutions, with a 15+ year history of NHS trust and endorsement from eyecare professionals.
Differentiator
Problem solved
Functional benefit
Brands
- Clinitas: Dry eye treatment product line including Clinitas 0.2% Ease, Clinitas 0.4% Soothe, and Clinitas Gel Hydrate, formulated with sodium hyaluronate for ocular surface relief.
Products and services
- Clinitas 0.2% Ease Ophthalmic solution of high-molecular weight sodium hyaluronate at 0.2% concentration designed to lubricate, moisturize, and protect the tear film. Provides relief from dry eye symptoms such as irritation, dryness, burning, and foreign body sensation. Available in multi-dose bottles and daily-dose vials, and suitable for use with contact lenses. Targeted at individual consumers experiencing mild dry eye symptoms and at eye care professionals recommending treatment to patients.
- Clinitas 0.4% Soothe Ophthalmic solution of high-molecular weight sodium hyaluronate at 0.4% concentration providing long-lasting, more intensive lubrication and protection for the ocular surface. Targeted at individuals with more severe or persistent dry eye symptoms and used by eye care professionals as a first-choice lubricating drop. Available in multi-dose bottles and daily-dose vials.
- Clinitas Gel Hydrate Lubricating carbomer 980 eye gel for relief of dry eye discomfort. Provides cooling and soothing relief for sore, gritty, and itchy eyes, and is used for nighttime relief or when a more viscous solution than drops is required. Targeted at individual consumers with dry eye symptoms and at eye care professionals who recommend it as part of dry eye management.
Quantifiable outcome
- Trusted by NHS since 2007
- +1 more outcomes
Companies that use Altacor
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Altacor technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Altacor partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Fidia FarmaceuticicoreFidia Farmaceutici, an Italian pharmaceutical company, acquired UK-based specialist ophthalmology company Altacor. The acquisition brings Altacor's growing portfolio including Clinitas dry eye treatment products into Fidia's ophthalmology portfolio. This represents a significant ownership change, with Altacor becoming a subsidiary of the Italian pharmaceutical group.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Altacor competitors and assessment
Company assessmentDirect peers
- Scope Ophthalmics (Hycosan): Scope Ophthalmics markets the Hycosan range of sodium hyaluronate-based dry eye drops in the UK, directly competing with Clinitas on formulation, channel (NHS + pharmacy), and target prescriber base.
- Thea Pharmaceuticals (Thealoz Duo): Thea Pharmaceuticals is a European specialty ophthalmology company whose Thealoz Duo combines trehalose and sodium hyaluronate for dry eye, competing head-to-head with Clinitas in UK and European optometry and ophthalmology channels.
Broad incumbents
- Alcon (Systane): Alcon's Systane is a global market-leading dry eye lubricant brand available in UK pharmacy and optometry channels, representing the principal mass-market incumbent competing with Clinitas.
- Bausch + Lomb (Artelac): Bausch + Lomb's Artelac range is a long-established European dry eye lubricant brand distributed through UK pharmacies and optometrists, overlapping with Clinitas on patient base and channel.
- Reckitt Benckiser (Optrex): Reckitt's Optrex is a UK household OTC eye care brand sold in mass-market pharmacy and grocery channels, competing with Clinitas on consumer-facing dry eye shelf space and brand awareness.
- Santen Pharmaceutical: Santen is a Japanese specialty ophthalmology company with a broad dry eye portfolio including Hyalein and Cationorm, competing with Clinitas across European prescription and OTC channels.
- Johnson & Johnson Vision (Blink / Refresh): Johnson & Johnson Vision's Blink and Refresh Tears brands are mass-market dry eye lubricants sold globally and in the UK, competing directly with Clinitas on consumer-facing positioning and pharmacy distribution.
- AbbVie / Allergan (Refresh): AbbVie's Allergan Aesthetics division owns the Refresh dry eye brand, a global incumbent in lubricant eye drops that competes with Clinitas on UK pharmacy shelves and optometrist recommendations.
Emerging players
- Novaliq (NovaTears / Evotears): Novaliq is a German specialty ophthalmology company developing water-free and cationic emulsion dry eye therapies (NovaTears, Evotears), offering a more differentiated mechanism of action than traditional HA-based products like Clinitas.
- Ocular Therapeutix: Ocular Therapeutix is a US-based specialty ophthalmology company focused on sustained-release ocular drug delivery and dry eye therapeutics, representing an emerging adjacent competitor in the broader dry eye treatment space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Altacor social profiles
Digital presenceAltacor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altacor leadership team
Management profileNumber of profiles
Profiles1 record
Altacor funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altacor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altacor
What does Altacor do?
Altacor develops, manufactures, and sells the Clinitas brand of ophthalmic products for the treatment of dry eye symptoms. The portfolio includes two sodium hyaluronate eye drop concentrations (Clinitas 0.2% Ease and Clinitas 0.4% Soothe) and a carbomer 980-based lubricating gel (Clinitas Gel Hydrate), formulated with high-molecular weight sodium hyaluronate to provide long-lasting ocular surface hydration. Products are sold primarily via the company's UK direct-to-consumer e-commerce store (clinitas.co.uk), with institutional use by the NHS.
Is Altacor a public or private company?
Altacor is a private company. It is classified as corporate owned and is currently acquired.
When was Altacor founded?
Altacor was founded in 2005. It employs 11 to 50 people.
Where is Altacor based?
Altacor is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Altacor make money?
One revenue line is on record: consumer Product Sales.
Who are Altacor's main competitors?
Direct peers on record are Scope Ophthalmics (Hycosan) and Thea Pharmaceuticals (Thealoz Duo). Broad incumbents are Alcon (Systane), Bausch + Lomb (Artelac), Reckitt Benckiser (Optrex), Santen Pharmaceutical, Johnson & Johnson Vision (Blink / Refresh) and AbbVie / Allergan (Refresh). Emerging players are Novaliq (NovaTears / Evotears) and Ocular Therapeutix.
Does Altacor have an API?
No public API is recorded for Altacor.
What industry is Altacor in?
Altacor's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAJAF, Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation). Its NAICS code is 339115 and its SIC code is 3851.